Prospective Grant of Exclusive Patent License: The Development of Monospecific and Bispecific Antibodies to GPC3 for the Treatment of Human Liver Cancers, 23013-23014 [2017-10154]
Download as PDF
Federal Register / Vol. 82, No. 96 / Friday, May 19, 2017 / Notices
Dated: May 11, 2017.
Richard U. Rodriguez,
Associate Director, Technology Transfer
Center, National Cancer Institute.
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
[FR Doc. 2017–10153 Filed 5–18–17; 8:45 am]
Prospective Grant of Exclusive Patent
License: The Development of
Monospecific and Bispecific
Antibodies to GPC3 for the Treatment
of Human Liver Cancers
National Institutes of Health
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
AGENCY:
ACTION:
National Institute on Alcohol Abuse
and Alcoholism; Notice of Closed
Meeting
asabaliauskas on DSK3SPTVN1PROD with NOTICES
Name of Committee: National Institute on
Alcohol Abuse and Alcoholism Special
Emphasis Panel; NIAAA Fellowship Review.
Date: July 21, 2017.
Time: 8:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
National Institute on Alcohol Abuse and
Alcoholism, Terrace Level Conference Room,
5635 Fishers Lane, Bethesda, M.D 20892
Contact Person: Richard A. Rippe, Ph.D.,
Scientific Review Officer , Extramural Project
Review Branch, Office of Extramural
Activities, National Institute on Alcohol
Abuse and Alcoholism, 5635 Fishers Lane,
Room 2109, Rockville, MD 20852, 301–443–
8599, rippera@mail.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.271, Alcohol Research
Career Development Awards for Scientists
and Clinicians; 93.272, Alcohol National
Research Service Awards for Research
Training; 93.273, Alcohol Research Programs;
93.891, Alcohol Research Center Grants;
93.701, ARRA Related Biomedical Research
and Research Support Awards., National
Institutes of Health, HHS)
Dated: May 15, 2017.
Melanie J. Pantoja,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2017–10113 Filed 5–18–17; 8:45 am]
BILLING CODE 4140–01–P
19:15 May 18, 2017
Jkt 241001
Notice.
The National Cancer Institute,
National Institutes of Health,
Department of Health and Human
Services, is contemplating the grant of
an Exclusive Patent License to AbPro,
located in Woburn, Massachusetts, to
practice the inventions embodied in the
patent applications listed in the
SUPPLEMENTARY INFORMATION section of
this notice.
DATES: Only written comments and/or
applications for a license which are
received by the NCI Technology
Transfer Center on or before June 5,
2017 will be considered.
ADDRESSES: Requests for copies of the
patent applications, inquiries, and
comments relating to the contemplated
Exclusive Patent License should be
directed to: David A. Lambertson, Ph.D.,
Senior Licensing and Patenting
Manager, NCI Technology Transfer
Center, 9609 Medical Center Drive, RM
1E530 MSC 9702, Bethesda, MD 20892–
9702 (for business mail), Rockville, MD
20850–9702, Telephone: (240)–276–
6467; Email: david.lambertson@nih.gov.
SUPPLEMENTARY INFORMATION: The
following represents the intellectual
property to be licensed under the
prospective agreement: U.S. Provisional
Patent Application 61/654,232 entitled
‘‘High-affinity Monoclonal Antibodies
To Glypican-3 And Use Thereof’’ [HHS
Ref. E–136–2012/0–US–01], PCT Patent
Application PCT/US2013/043633
entitled ‘‘High-affinity Monoclonal
Antibodies To Glypican-3 And Use
Thereof’’ [HHS Ref. E–136–2012/0–
PCT–02], Chinese Patent Application
201380039993.7 entitled ‘‘High-affinity
Monoclonal Antibodies To Glypican-3
And Use Thereof’’ [HHS Ref. E–136–
2012/0–CN–03], Japanese Patent
Application 2015–515243 entitled
‘‘High-affinity Monoclonal Antibodies
To Glypican-3 And Use Thereof’’ [HHS
Ref. E–136–2012/0–JP–04], South
Korean Patent Application 10–2014–
7037046 entitled ‘‘High-affinity
Monoclonal Antibodies To Glypican-3
And Use Thereof’’ [HHS Ref. E–136–
2012/0–KR–05], Singapore Patent
Application 11201407972R entitled
SUMMARY:
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
VerDate Sep<11>2014
National Institutes of Health,
HHS.
National Institutes of Health
PO 00000
Frm 00061
Fmt 4703
Sfmt 4703
23013
‘‘High-affinity Monoclonal Antibodies
To Glypican-3 And Use Thereof’’ [HHS
Ref. E–136–2012/0–SG–06], and United
States Patent 9,409,994 entitled ‘‘Highaffinity Monoclonal Antibodies To
Glypican-3 And Use Thereof’’ [HHS Ref.
E–136–2012/0–US–07], and all
continuing U.S. and foreign patents/
patent applications for the technology
family, to AbPro. The patent rights in
these inventions have been assigned to
and/or exclusively licensed to the
Government of the United States of
America.
With respect to persons who have an
obligation to assign their right, title and
interest to the Government of the United
States of America, the patent rights in
these inventions have been assigned to
the Government of the United States of
America.
The prospective Exclusive Patent
License territory may be worldwide for
the following field of use:
The use of the YP7, YP8 and YP9.1 antiGPC3 monoclonal antibodies as monospecific
or bispecific antibodies for the treatment of
liver cancer. The licensed field of use
excludes any non-specified
immunoconjugates, including, but not
limited to, chimeric antigen receptors (CARs)
and variants thereof, Immunotoxins, and
antibody-drug conjugates (ADCs).
The present inventions to be licensed
concern monoclonal antibodies that are
specific for the cell surface domain of
GPC3: YP6, YP7, YP8, YP9 and YP9.1.
These antibodies can potentially be
used for the treatment of GPC3expressing cancers such as HCC. By
binding to and blocking GPC3 function,
these antibodies can inhibit the growth
of HCC cells, thereby decreasing the
ability of tumors to grow and
metastasize. Alternatively, the
antibodies can be used to induce
antibody-dependent anti-tumor activity
by selectively killing cells which
overexpress GPC3 while leaving
healthy, normal cells unscathed.
Finally, a secondary antibody capable of
recruiting T cells to the tumor can be
attached to the antibodies, thereby
allowing for the localization of T cells
or NK cells only to those cells which
express GPC3, similarly leading to the
selective killing of the cancer cells.
This notice is made in accordance
with 35 U.S.C. 209 and 37 CFR part 404.
The prospective Exclusive Patent
License will be royalty bearing and may
be granted unless within fifteen (15)
days from the date of this published
notice, the National Cancer Institute
receives written evidence and argument
that establishes that the grant of the
license would not be consistent with the
requirements of 35 U.S.C. 209 and 37
CFR part 404.
E:\FR\FM\19MYN1.SGM
19MYN1
23014
Federal Register / Vol. 82, No. 96 / Friday, May 19, 2017 / Notices
Complete applications for a license in
the prospective field of use that are
timely filed in response to this notice
will be treated as objections to the grant
of the contemplated Exclusive Patent
License. Comments and objections
submitted to this notice will not be
made available for public inspection
and, to the extent permitted by law, will
not be released under the Freedom of
Information Act, 5 U.S.C. 552.
Dated: May 11, 2017.
Richard U. Rodriguez,
Associate Director, Technology Transfer
Center, National Cancer Institute.
[FR Doc. 2017–10154 Filed 5–18–17; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Prospective Grant of an Exclusive
Patent License: Manufacturing and
Testing of PVSRIPO in the Treatment
of Solid, Non-lymphoid Tumors
Expressing Poliovirus Receptor CD155
AGENCY:
National Institutes of Health,
HHS.
ACTION:
Notice.
The National Cancer Institute,
an institute of the National Institutes of
Health, Department of Health and
Human Services, is contemplating the
grant of an Exclusive Commercialization
Patent License to practice the inventions
embodied in the Patents and Patent
Applications listed in the
Supplementary Information section of
this notice to Istari Oncology
Incorporated located in North Carolina,
U.S.A.
DATES: Only written comments and/or
applications for a license which are
received by the National Cancer
Institute’s Technology Transfer Center
on or before June 5, 2017 will be
considered.
SUMMARY:
Requests for copies of the
patent application, inquiries, and
comments relating to the contemplated
Exclusive Commercialization Patent
License should be directed to: Lauren
Nguyen-Antczak, Ph.D., J.D., Senior
Licensing and Patenting Manager, NCI
Technology Transfer Center, 9609
Medical Center Drive, RM 1E530 MSC
9702, Bethesda, MD 20892–9702 (for
business mail), Rockville, MD 20850–
9702, Telephone: (240) 276–5530;
Facsimile: (240) 276–5504, Email:
lauren.nguyen-antczak@nih.gov.
SUPPLEMENTARY INFORMATION:
asabaliauskas on DSK3SPTVN1PROD with NOTICES
ADDRESSES:
VerDate Sep<11>2014
19:15 May 18, 2017
Jkt 241001
Intellectual Property
United States Provisional Patent
Application No. 62/173,777, filed June
10, 2015 and entitled ‘‘Processes for
Production and Purification of Nucleic
Acid Containing Compositions’’ [HHS
Reference No. E–267–2014/0–US–01];
PCT Patent Application PCT/US2016/
036888, filed E–267–2014/0–PCT–02
and entitled ‘‘Processes for Production
and Purification of Nucleic Acid
Containing Compositions’’ [HHS
Reference No. E–267–2014/0–PCT–02];
United States Provisional Patent
Application No. 62/199,663, filed July
31, 2015 and entitled ‘‘Methods of
Analyzing Virus-Derived Therapeutics’’
[HHS Reference No. E–240–2015/0–US–
01];
PCT Patent Application PCT/US2016/
044788, filed July 29, 2016 and entitled
‘‘Methods of Analyzing Virus-Derived
Therapeutics’’ [HHS Reference No. E–
240–2015/1–PCT–01]; and U.S. and
foreign patent applications claiming
priority to the aforementioned
applications.
The patent rights in these inventions
have been assigned and/or exclusively
licensed to the government of the
United States of America.
The prospective exclusive license
territory may be worldwide and the
field of use may be limited to the use
of Licensed Patent Rights for the
following: ‘‘Manufacturing and Testing
of PVSRIPO in the Treatment of Solid,
Non-lymphoid Tumors expressing
Poliovirus Receptor CD155, wherein
PVSRIPO is genetically recombinant,
non-pathogenic poliovirus:rhinovirus
chimera that consists of the genome of
the live attenuated poliovirus serotype 1
(SABIN) vaccine (PV1S) with its cognate
IRES element replaced with that of
HRV2.’’
The E–267–2014 technology discloses
improved methods for large scale
production of highly purified,
therapeutic grade, oncolytic
polioviruses. Invention processes
provide industrial scale, and cGMP
compliant manufacturing of PVSRIPO.
The E–240–2015 technology discloses
improved methods for detecting genetic
micro-heterogeneity in manufactured
batches of RNA virus-derived
therapeutics, such as PVSRIPO.
This notice is made in accordance
with 35 U.S.C. 209 and 37 CFR part 404.
The prospective exclusive license will
be royalty bearing, and the prospective
exclusive license may be granted unless
within fifteen (15) days from the date of
this published notice, the National
Cancer Institute receives written
evidence and argument that establishes
that the grant of the license would not
PO 00000
Frm 00062
Fmt 4703
Sfmt 4703
be consistent with the requirements of
35 U.S.C. 209 and 37 CFR part 404.
Complete applications for a license in
the prospective field of use that are filed
in response to this notice will be treated
as objections to the grant of the
contemplated Exclusive
Commercialization Patent License
Agreement. Comments and objections
submitted to this notice will not be
made available for public inspection
and, to the extent permitted by law, will
not be released under the Freedom of
Information Act, 5 U.S.C. 552.
Dated: May 12, 2017.
Richard U. Rodriguez,
Associate Director, Technology Transfer
Center, National Cancer Institute.
[FR Doc. 2017–10155 Filed 5–18–17; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions;
Availability for Licensing
AGENCY:
National Institutes of Health,
HHS.
ACTION:
Notice.
The invention listed below is
owned by an agency of the U.S.
Government and is available for
licensing to achieve expeditious
commercialization of results of
federally-funded research and
development. Foreign patent
applications are filed on selected
inventions to extend market coverage
for companies and may also be available
for licensing.
FOR FURTHER INFORMATION CONTACT: Dr.
Dianca Finch, 240–669–5503;
dianca.finch@nih.gov. Licensing
information and copies of the patent
applications listed below may be
obtained by communicating with the
indicated licensing contact at the
Technology Transfer and Intellectual
Property Office, National Institute of
Allergy and Infectious Diseases, 5601
Fishers Lane, Rockville, MD, 20852; tel.
301–496–2644. A signed Confidential
Disclosure Agreement will be required
to receive copies of unpublished patent
applications.
SUPPLEMENTARY INFORMATION:
Technology description follows.
SUMMARY:
Products for Treatment and Prevention
of Ebola Zaire Disease
Description of Technology
Scientists at the NIAID Vaccine
Research Center have developed human
E:\FR\FM\19MYN1.SGM
19MYN1
Agencies
[Federal Register Volume 82, Number 96 (Friday, May 19, 2017)]
[Notices]
[Pages 23013-23014]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2017-10154]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Prospective Grant of Exclusive Patent License: The Development of
Monospecific and Bispecific Antibodies to GPC3 for the Treatment of
Human Liver Cancers
AGENCY: National Institutes of Health, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The National Cancer Institute, National Institutes of Health,
Department of Health and Human Services, is contemplating the grant of
an Exclusive Patent License to AbPro, located in Woburn, Massachusetts,
to practice the inventions embodied in the patent applications listed
in the SUPPLEMENTARY INFORMATION section of this notice.
DATES: Only written comments and/or applications for a license which
are received by the NCI Technology Transfer Center on or before June 5,
2017 will be considered.
ADDRESSES: Requests for copies of the patent applications, inquiries,
and comments relating to the contemplated Exclusive Patent License
should be directed to: David A. Lambertson, Ph.D., Senior Licensing and
Patenting Manager, NCI Technology Transfer Center, 9609 Medical Center
Drive, RM 1E530 MSC 9702, Bethesda, MD 20892-9702 (for business mail),
Rockville, MD 20850-9702, Telephone: (240)-276-6467; Email:
david.lambertson@nih.gov.
SUPPLEMENTARY INFORMATION: The following represents the intellectual
property to be licensed under the prospective agreement: U.S.
Provisional Patent Application 61/654,232 entitled ``High-affinity
Monoclonal Antibodies To Glypican-3 And Use Thereof'' [HHS Ref. E-136-
2012/0-US-01], PCT Patent Application PCT/US2013/043633 entitled
``High-affinity Monoclonal Antibodies To Glypican-3 And Use Thereof''
[HHS Ref. E-136-2012/0-PCT-02], Chinese Patent Application
201380039993.7 entitled ``High-affinity Monoclonal Antibodies To
Glypican-3 And Use Thereof'' [HHS Ref. E-136-2012/0-CN-03], Japanese
Patent Application 2015-515243 entitled ``High-affinity Monoclonal
Antibodies To Glypican-3 And Use Thereof'' [HHS Ref. E-136-2012/0-JP-
04], South Korean Patent Application 10-2014-7037046 entitled ``High-
affinity Monoclonal Antibodies To Glypican-3 And Use Thereof'' [HHS
Ref. E-136-2012/0-KR-05], Singapore Patent Application 11201407972R
entitled ``High-affinity Monoclonal Antibodies To Glypican-3 And Use
Thereof'' [HHS Ref. E-136-2012/0-SG-06], and United States Patent
9,409,994 entitled ``High-affinity Monoclonal Antibodies To Glypican-3
And Use Thereof'' [HHS Ref. E-136-2012/0-US-07], and all continuing
U.S. and foreign patents/patent applications for the technology family,
to AbPro. The patent rights in these inventions have been assigned to
and/or exclusively licensed to the Government of the United States of
America.
With respect to persons who have an obligation to assign their
right, title and interest to the Government of the United States of
America, the patent rights in these inventions have been assigned to
the Government of the United States of America.
The prospective Exclusive Patent License territory may be worldwide
for the following field of use:
The use of the YP7, YP8 and YP9.1 anti-GPC3 monoclonal
antibodies as monospecific or bispecific antibodies for the
treatment of liver cancer. The licensed field of use excludes any
non-specified immunoconjugates, including, but not limited to,
chimeric antigen receptors (CARs) and variants thereof,
Immunotoxins, and antibody-drug conjugates (ADCs).
The present inventions to be licensed concern monoclonal antibodies
that are specific for the cell surface domain of GPC3: YP6, YP7, YP8,
YP9 and YP9.1. These antibodies can potentially be used for the
treatment of GPC3-expressing cancers such as HCC. By binding to and
blocking GPC3 function, these antibodies can inhibit the growth of HCC
cells, thereby decreasing the ability of tumors to grow and
metastasize. Alternatively, the antibodies can be used to induce
antibody-dependent anti-tumor activity by selectively killing cells
which overexpress GPC3 while leaving healthy, normal cells unscathed.
Finally, a secondary antibody capable of recruiting T cells to the
tumor can be attached to the antibodies, thereby allowing for the
localization of T cells or NK cells only to those cells which express
GPC3, similarly leading to the selective killing of the cancer cells.
This notice is made in accordance with 35 U.S.C. 209 and 37 CFR
part 404. The prospective Exclusive Patent License will be royalty
bearing and may be granted unless within fifteen (15) days from the
date of this published notice, the National Cancer Institute receives
written evidence and argument that establishes that the grant of the
license would not be consistent with the requirements of 35 U.S.C. 209
and 37 CFR part 404.
[[Page 23014]]
Complete applications for a license in the prospective field of use
that are timely filed in response to this notice will be treated as
objections to the grant of the contemplated Exclusive Patent License.
Comments and objections submitted to this notice will not be made
available for public inspection and, to the extent permitted by law,
will not be released under the Freedom of Information Act, 5 U.S.C.
552.
Dated: May 11, 2017.
Richard U. Rodriguez,
Associate Director, Technology Transfer Center, National Cancer
Institute.
[FR Doc. 2017-10154 Filed 5-18-17; 8:45 am]
BILLING CODE 4140-01-P